Roles of fibrin(ogen) in conformational activation of hemostatic proteinase precursors
纤维蛋白(原)在止血蛋白酶前体构象激活中的作用
基本信息
- 批准号:10620293
- 负责人:
- 金额:$ 47.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-10 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:Active SitesAntibiotic ResistanceAntibodiesAntiplasminBacterial EndocarditisBacterial ProteinsBindingBinding SitesBlocking AntibodiesBlood Coagulation DisordersC-terminalCatalytic DomainChurchCoagulation ProcessCollaborationsCombined Modality TherapyComplexCross ReactionsCryoelectron MicroscopyDataDevelopmentEnvironmentEnzyme PrecursorsEpitopesEquilibriumEvaluationExtracellular Matrix ProteinsFibrinFibrin fragment DFibrinogenFluorescenceFundingFutureGoalsHemostatic AgentsHemostatic functionHost Defense MechanismHumanIn VitroInfectionInnate Immune SystemInvadedKineticsKnowledgeMediatingMethodsModelingMolecular ConformationMonoclonal AntibodiesN-terminalPatientsPeptide HydrolasesPhysiologicalPlasminPlasminogenPreclinical TestingProteinsProthrombinQualifyingRegulationResourcesRiskRoleScanningSerotypingStaphylocoagulaseStaphylococcus aureusStreptococcus pyogenesStreptokinaseStructureSurfaceSystemTerminal Repeat SequencesTestingTherapeutic EmbolizationTherapeutic antibodiesThrombinThrombosisTissuesTrypsinVaccinesVariantVirulence FactorsWorkactivation productbacterial resistancecofactordesignexpression vectorgenetic varianthumanized monoclonal antibodiesin vivoin vivo evaluationin vivo imaginginhibitormouse modelmurine monoclonal antibodynovelnovel therapeuticspreventresearch clinical testingside effect
项目摘要
Prothrombin and plasminogen, two central hemostatic zymogens, are activated proteolytically by cleavage of an
activation loop. The newly formed N-terminus inserts into a binding pocket and triggers formation of a functional
active site. The activation products thrombin and plasmin respectively form and degrade fibrin, but physiological
regulation prevents uncontrolled clotting and promiscuous plasmin-mediated tissue degradation. The bacterial
virulence factors, staphylocoagulase (SC) and streptokinase (SK), hijack this mechanism by inserting their own
N-termini into the host zymogen pockets, and conformationally activating the catalytic site. The SK-plasminogen
complex proteolytically activates plasminogen to plasmin. Both the SC and SK complexes with the zymogens
and the mature proteases cleave fibrin(ogen) but are impervious to host antithrombin and antiplasmin, and
alternative methods are needed to zcontrol their unwanted activity. Our monoclonal antibodies (mAbs) against
the SC and SK N-termini block complex formation and activity, counteracting infection-related thrombosis and
bacterial spreading in vivo. This illustrates mechanism-based mAb feasibility in an environment of increasing
antibiotic resistance. SC and SK have additional, incompletely defined binding sites for fibrin(ogen) independent
of substrate recognition, that play a role in localization. Our proposal aims to identify unique SC and SK
sequences, and conformational epitopes in their complexes with the zymogens, that promote binding of
fibrin(ogen), both in substrate and anchoring modes. Our group has long-standing expertise with SC and SK-
mediated zymogen activation, and we recently made good progress identifying fibrin(ogen) fragment D binding
to the C-terminal repeats of SC. However, interactions of the SK-plasmin(ogen) complexes with host fibrin(ogen)
are still not well understood. Our short-term goals are to define fibrin(ogen) binding, enhancement of cofactor-
zymogen reactivity by fibrin(ogen), identify binding epitopes, and develop in vivo effective mAbs that will be
added to our existing antibody arsenal. We combine our structure-function and mechanism expertise with that
of experts in mAb development (Dr. Bill Church), and in application of mouse models of SC and SK action (Dr.
Peter Panizzi). Aim 1 will define dual interaction mechanisms of the SC-prothrombin complex with fibrin(ogen),
with the goal of identifying suitable linear and conformational epitopes for blocking fibrin(ogen) binding. Aim 2
will delineate fibrin(ogen)-dependent plasminogen activation mechanisms of S. pyogenes SK variants that to
date are not well defined, with the same goal of identifying fibrin(ogen)-binding epitopes on the SK variants. Aim
3 will test our humanized mAbs targeting the N-termini of SC and SK in vivo, and select tight-binding anti-
fibrin(ogen) binding site mAbs for in vivo studies. Long-term goals for future funding cycles are the development
of mAbs that that cross-react with a wide range of serotypes and allelic variants, and may qualify for pre-clinical
and clinical testing. Cocktails of these mAbs would support the patient's hemostatic system by minimizing
plasmin-mediated bacterial spreading and unwanted prothrombin activation without causing bacterial resistance.
凝血酶原和纤溶酶原是两种中枢止血酶原,通过裂解
激活循环。新形成的 N 末端插入结合口袋并触发功能性结构的形成
活跃站点。激活产物凝血酶和纤溶酶分别形成和降解纤维蛋白,但生理上
调节可防止不受控制的凝血和混杂的纤溶酶介导的组织降解。细菌
毒力因子,葡萄球菌凝固酶(SC)和链激酶(SK),通过插入自己的基因来劫持该机制
N-末端进入宿主酶原口袋,并构象激活催化位点。 SK-纤溶酶原
复合物通过蛋白水解将纤溶酶原激活为纤溶酶。 SC 和 SK 均与酶原形成复合物
成熟的蛋白酶裂解纤维蛋白(原),但不受宿主抗凝血酶和抗纤溶酶的影响,并且
需要替代方法来控制其不需要的活动。我们的单克隆抗体 (mAb)
SC 和 SK N 末端阻断复合物的形成和活性,对抗感染相关的血栓形成和
细菌在体内传播。这说明了基于机制的 mAb 在日益增加的环境中的可行性
抗生素耐药性。 SC 和 SK 具有额外的、不完全定义的独立于纤维蛋白(原)的结合位点
底物识别,在定位中发挥作用。我们的提案旨在确定独特的 SC 和 SK
其与酶原的复合物中的序列和构象表位,促进结合
纤维蛋白(原),无论是底物模式还是锚定模式。我们的团队在 SC 和 SK 方面拥有长期的专业知识-
介导的酶原激活,我们最近在鉴定纤维蛋白(原)片段 D 结合方面取得了良好进展
至 SC 的 C 末端重复。然而,SK-纤溶酶(原)复合物与宿主纤维蛋白(原)的相互作用
仍然没有得到很好的理解。我们的短期目标是定义纤维蛋白(原)结合,增强辅因子-
纤维蛋白(原)的酶原反应性,识别结合表位,并开发体内有效的单克隆抗体
添加到我们现有的抗体库中。我们将我们的结构功能和机制专业知识与此相结合
mAb 开发专家(Bill Church 博士)以及 SC 和 SK 作用小鼠模型的应用(Dr.
彼得·帕尼兹)。目标 1 将定义 SC-凝血酶原复合物与纤维蛋白(原)的双重相互作用机制,
目的是确定合适的线性和构象表位来阻断纤维蛋白(原)结合。目标2
将描述化脓性链球菌 SK 变体的纤维蛋白(原)依赖性纤溶酶原激活机制
日期尚未明确定义,其相同目标是识别 SK 变体上的纤维蛋白(原)结合表位。目的
3 将在体内测试我们针对 SC 和 SK N 末端的人源化 mAb,并选择紧密结合的抗
用于体内研究的纤维蛋白(原)结合位点单克隆抗体。未来融资周期的长期目标是发展
与多种血清型和等位基因变体发生交叉反应的单克隆抗体,可能有资格进行临床前试验
和临床测试。这些单克隆抗体的混合物将通过最大限度地减少血液循环来支持患者的止血系统。
纤溶酶介导的细菌传播和不需要的凝血酶原激活,而不引起细菌耐药性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
INGRID M VERHAMME其他文献
INGRID M VERHAMME的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('INGRID M VERHAMME', 18)}}的其他基金
Roles of fibrin(ogen) in conformational activation of hemostatic proteinase precursors
纤维蛋白(原)在止血蛋白酶前体构象激活中的作用
- 批准号:
10453034 - 财政年份:2022
- 资助金额:
$ 47.75万 - 项目类别:
Mechanisms of Glycosaminoglycan-Catalyzed Protease Inactivation by Serpins
丝氨酸蛋白酶抑制剂 (Serpin) 糖胺聚糖催化的蛋白酶灭活机制
- 批准号:
9335436 - 财政年份:2016
- 资助金额:
$ 47.75万 - 项目类别:
Mechanisms of Glycosaminoglycan-Catalyzed Protease Inactivation by Serpins
丝氨酸蛋白酶抑制剂 (Serpin) 糖胺聚糖催化的蛋白酶灭活机制
- 批准号:
9175213 - 财政年份:2016
- 资助金额:
$ 47.75万 - 项目类别:
Mechanisms of Hemostatic Protease Inhibition by Serpins
丝氨酸蛋白酶抑制剂抑制止血蛋白酶的机制
- 批准号:
7837515 - 财政年份:2009
- 资助金额:
$ 47.75万 - 项目类别:
Mechanisms of Hemostatic Protease Inhibition by Serpins
丝氨酸蛋白酶抑制剂抑制止血蛋白酶的机制
- 批准号:
7540399 - 财政年份:2006
- 资助金额:
$ 47.75万 - 项目类别:
Mechanisms of Hemostatic Protease Inhibition by Serpins
丝氨酸蛋白酶抑制剂抑制止血蛋白酶的机制
- 批准号:
7173010 - 财政年份:2006
- 资助金额:
$ 47.75万 - 项目类别:
Mechanisms of Hemostatic Protease Inhibition by Serpins
丝氨酸蛋白酶抑制剂抑制止血蛋白酶的机制
- 批准号:
7754418 - 财政年份:2006
- 资助金额:
$ 47.75万 - 项目类别:
Mechanisms of Hemostatic Protease Inhibition by Serpins
丝氨酸蛋白酶抑制剂抑制止血蛋白酶的机制
- 批准号:
7047586 - 财政年份:2006
- 资助金额:
$ 47.75万 - 项目类别:
Mechanisms of Hemostatic Protease Inhibition by Serpins
丝氨酸蛋白酶抑制剂抑制止血蛋白酶的机制
- 批准号:
7338327 - 财政年份:2006
- 资助金额:
$ 47.75万 - 项目类别:
相似海外基金
Ecological and Evolutionary Drivers of Antibiotic Resistance in Patients
患者抗生素耐药性的生态和进化驱动因素
- 批准号:
EP/Y031067/1 - 财政年份:2024
- 资助金额:
$ 47.75万 - 项目类别:
Research Grant
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
- 批准号:
2307222 - 财政年份:2024
- 资助金额:
$ 47.75万 - 项目类别:
Standard Grant
Molecular Epidemiology of Antibiotic Resistance in Clostridioides difficile
艰难梭菌抗生素耐药性的分子流行病学
- 批准号:
502587 - 财政年份:2024
- 资助金额:
$ 47.75万 - 项目类别:
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
- 批准号:
2307223 - 财政年份:2024
- 资助金额:
$ 47.75万 - 项目类别:
Standard Grant
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 47.75万 - 项目类别:
Research Grant
Determining structural dynamics of membrane proteins in their native environment: focus on bacterial antibiotic resistance
确定膜蛋白在其天然环境中的结构动力学:关注细菌抗生素耐药性
- 批准号:
MR/X009580/1 - 财政年份:2024
- 资助金额:
$ 47.75万 - 项目类别:
Fellowship
CAREER: Systems Microbiology and InterdiscipLinary Education for Halting Environmental Antibiotic Resistance Transmission (SMILE HEART)
职业:阻止环境抗生素耐药性传播的系统微生物学和跨学科教育(SMILE HEART)
- 批准号:
2340818 - 财政年份:2024
- 资助金额:
$ 47.75万 - 项目类别:
Continuing Grant
Reinforcing the battle at the bacterial cell wall: Structure-guided characterization and inhibition of beta-lactam antibiotic resistance signalling mechanisms
加强细菌细胞壁的战斗:β-内酰胺抗生素耐药信号机制的结构引导表征和抑制
- 批准号:
480022 - 财政年份:2023
- 资助金额:
$ 47.75万 - 项目类别:
Operating Grants
The spread of antibiotic resistance in bacteria-plasmid networks
抗生素耐药性在细菌-质粒网络中的传播
- 批准号:
BB/X010473/1 - 财政年份:2023
- 资助金额:
$ 47.75万 - 项目类别:
Fellowship
An RNA Nanosensor for the Diagnosis of Antibiotic Resistance in M. Tuberculosis
用于诊断结核分枝杆菌抗生素耐药性的 RNA 纳米传感器
- 批准号:
10670613 - 财政年份:2023
- 资助金额:
$ 47.75万 - 项目类别:














{{item.name}}会员




